E01B0391 Human Bone Morphogenetic Protein 9 ELISA kit
The Human Bone Morphogenetic Protein 9 ELISA kit can be used to identify samples from the human species. Bone Morphogenetic Protein 9 can also be called BMP9, GDF2, BMP-9, BMP9, HHT5, GDF-2, growth differentiation factor 2.
Product Information | |
Cat. No. | E01B0391 |
Product Name | Human Bone Morphogenetic Protein 9 ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 250-5000 pg/ml |
Sensitivity | 1.0 pg/ml |
Principal | Sandwich ELISA |
Sample Volume | 50 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 10.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 pg/mL | 1 vial |
STANDARD B (0.5mL) | 250 pg/mL | 1 vial |
STANDARD C (0.5mL) | 500 pg/mL | 1 vial |
STANDARD D (0.5mL) | 1000 pg/mL | 1 vial |
STANDARD E (0.5mL) | 2500 pg/mL | 1 vial |
STANDARD F (0.5mL) | 5000 pg/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
BMP9 ELISA kit applies the quantitative sandwich enzyme immunoassay technique. The microtiter plate has been pre-coated with a monoclonal antibody specific for BMP9. Standards or samples are then added to the microtiter plate wells and BMP9 if present, will bind to the antibody pre-coated wells. In order to quantitatively determine the amount of BMP9 present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for BMP9 are added to each well to “sandwich” the BMP9 immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound coBMP9nents. Next, substrate solutions are added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain BMP9 and enzyme-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The BMP9 concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between BMP9 and analogues was observed. | |
E01B0391 has been referenced in the below publications：
RESEARCH ABNORMAL BLOOD SUGAR IN HEAVY MEDITTERRANEAN ANEMIA PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTION AND RELATED INFLUENCE FACTORS.
Related Bluegene Biotech Products
BlueGene Biotech News
